Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
12
11
2019
accepted:
19
08
2020
revised:
22
06
2020
pubmed:
25
9
2020
medline:
16
4
2021
entrez:
24
9
2020
Statut:
ppublish
Résumé
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal with the detection of mutations. The analysis of cfDNA is often discussed in the context of the noninvasive detection of mutations that lead to resistance mechanisms and therapeutic and disease monitoring in cancer patients. Indeed, substantial advances have been made in this area, with the development of methods that reach high sensitivity and can interrogate a large number of genes. Interestingly, however, cfDNA can also be used to analyse different features of DNA, such as methylation status, size fragment patterns, transcriptomics and viral load, which open new avenues for the analysis of liquid biopsy samples from cancer patients. This review will focus on the new perspectives and challenges of cfDNA analysis from mutation detection in patients with solid malignancies.
Identifiants
pubmed: 32968207
doi: 10.1038/s41416-020-01047-5
pii: 10.1038/s41416-020-01047-5
pmc: PMC7852556
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
345-358Références
Mandel, P. & Metais, P. Les acides nucléiques du plasma sanguin chez l’homme. Comptes rendus des. seances de. la Soc. de. biologie et. de. ses. filiales 142, 241–243 (1948).
Lo, Y. M., Chan, K. C., Sun, H., Chen, E. Z., Jiang, P., Lun, F. M. et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci. Transl. Med. 2, 61ra91 (2010).
pubmed: 21148127
doi: 10.1126/scitranslmed.3001720
pmcid: 21148127
Knight, S. R., Thorne, A. & Lo Faro, M. L. Donor-specific cell-free DNA as a biomarker in solid organ transplantation. A systematic review. Transplantation 103, 273–283 (2019).
pubmed: 30308576
doi: 10.1097/TP.0000000000002482
pmcid: 30308576
Duvvuri, B. & Lood, C. Cell-Free DNA as a biomarker in autoimmune rheumatic diseases. Front. Immunol. 10, 502 (2019).
pubmed: 30941136
pmcid: 6433826
doi: 10.3389/fimmu.2019.00502
Lehmann-Werman, R., Magenheim, J., Moss, J., Neiman, D., Abraham, O., Piyanzin, S. et al. Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA. JCI Insight 3, e120687 (2018).
pmcid: 6124429
doi: 10.1172/jci.insight.120687
Zemmour, H., Planer, D., Magenheim, J., Moss, J., Neiman, D., Gilon, D. et al. Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA. Nat. Commun. 9, 1443 (2018).
pubmed: 29691397
pmcid: 5915384
doi: 10.1038/s41467-018-03961-y
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223–238 (2017).
pubmed: 28233803
doi: 10.1038/nrc.2017.7
pmcid: 28233803
van der Pol, Y. & Mouliere, F. Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA. Cancer Cell. 36, 350–368 (2019).
pubmed: 31614115
doi: 10.1016/j.ccell.2019.09.003
pmcid: 31614115
Kustanovich, A., Schwartz, R., Peretz, T. & Grinshpun, A. Life and death of circulating cell-free DNA. Cancer Biol. Ther. 20, 1057–1067 (2019).
pubmed: 30990132
pmcid: 6606043
doi: 10.1080/15384047.2019.1598759
Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451 (2017).
pubmed: 28445469
pmcid: 5812436
doi: 10.1038/nature22364
Mair, R., Mouliere, F., Smith, C. G., Chandrananda, D., Gale, D., Marass, F. et al. Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models. Cancer Res. 79, 220–230 (2019).
pubmed: 30389699
doi: 10.1158/0008-5472.CAN-18-0074
pmcid: 30389699
Wong, S. Q., Raleigh, J. M., Callahan, J., Vergara, I. A., Ftouni, S., Hatzimihalis, A. et al. Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma. JCO Precis. Oncol. 1, 1–14 (2017).
Lazaro-Ibanez, E., Lasser, C., Shelke, G. V., Crescitelli, R., Jang, S. C., Cvjetkovic, A. et al. DNA analysis of low- and high-density fractions defines heterogeneous subpopulations of small extracellular vesicles based on their DNA cargo and topology. J. Extracell. Vesicles 8, 1656993 (2019).
pubmed: 31497265
pmcid: 6719264
doi: 10.1080/20013078.2019.1656993
Vagner, T., Spinelli, C., Minciacchi, V. R., Balaj, L., Zandian, M., Conley, A. et al. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J. Extracell. Vesicles 7, 1505403 (2018).
pubmed: 30108686
pmcid: 6084494
doi: 10.1080/20013078.2018.1505403
Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71–88 (2019).
pubmed: 30410101
doi: 10.1038/s41576-018-0071-5
pmcid: 30410101
Feinberg, A. P., Koldobskiy, M. A. & Gondor, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284–299 (2016).
pubmed: 26972587
pmcid: 4888057
doi: 10.1038/nrg.2016.13
Boire, A., Brandsma, D., Brastianos, P. K., Le Rhun, E., Ahluwalia, M., Junck, L. et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol. 21, 571–584 (2019).
pubmed: 30668804
pmcid: 6502489
doi: 10.1093/neuonc/noz012
Abbou, S. D., Shulman, D. S., DuBois, S. G. & Crompton, B. D. Assessment of circulating tumor DNA in pediatric solid tumors: the promise of liquid biopsies. Pediatr. Blood Cancer 66, e27595 (2019).
pubmed: 30614191
pmcid: 6550461
doi: 10.1002/pbc.27595
Cristaldi, M., Mauceri, R., Di Fede, O., Giuliana, G., Campisi, G. & Panzarella, V. Salivary biomarkers for oral squamous cell carcinoma diagnosis and follow-up: current status and perspectives. Front. Physiol. 10, 1476 (2019).
pubmed: 31920689
pmcid: 6914830
doi: 10.3389/fphys.2019.01476
Ribeiro, I. P., de Melo, J. B. & Carreira, I. M. Head and neck cancer: searching for genomic and epigenetic biomarkers in body fluids—the state of art. Mol. Cytogenet. 12, 33 (2019).
pubmed: 31333762
pmcid: 6621978
doi: 10.1186/s13039-019-0447-z
Ponti, G., Manfredini, M. & Tomasi, A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Crit. Rev. Oncol. Hematol. 141, 36–42 (2019).
pubmed: 31212145
doi: 10.1016/j.critrevonc.2019.06.005
pmcid: 31212145
Elazezy, M. & Joosse, S. A. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput. Struct. Biotechnol. J. 16, 370–378 (2018).
pubmed: 30364656
pmcid: 6197739
doi: 10.1016/j.csbj.2018.10.002
Kwapisz, D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann. Transl. Med. 5, 46 (2017).
pubmed: 28251125
pmcid: 5326656
doi: 10.21037/atm.2017.01.32
Haselmann, V., Gebhardt, C., Brechtel, I., Duda, A., Czerwinski, C., Sucker, A. et al. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy. Clin. Chem. 64, 830–42. (2018).
pubmed: 29483107
doi: 10.1373/clinchem.2017.281543
pmcid: 29483107
Oshiro, C., Kagara, N., Naoi, Y., Shimoda, M., Shimomura, A., Maruyama, N. et al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res. Treat. 150, 299–307 (2015).
pubmed: 25736040
doi: 10.1007/s10549-015-3322-6
pmcid: 25736040
Kuo, Y. B., Chen, J. S., Fan, C. W., Li, Y. S. & Chan, E. C. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin. Chim. Acta 433, 284–289 (2014).
pubmed: 24685572
doi: 10.1016/j.cca.2014.03.024
pmcid: 24685572
Ou, C.-Y., Vu, T., Grunwald, J. T., Toledano, M., Zimak, J., Toosky, M. et al. An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection. Lab Chip 19, 993–1005 (2019).
pubmed: 30735225
doi: 10.1039/C8LC01399C
pmcid: 30735225
Pantel, K. & Alix-Panabieres, C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat. Rev. Clin. Oncol. 16, 409–24. (2019).
pubmed: 30796368
doi: 10.1038/s41571-019-0187-3
pmcid: 30796368
Tan, L., Sandhu, S., Lee, R. J., Li, J., Callahan, J., Ftouni, S. et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann. Oncol. 30, 804–14. (2019).
pubmed: 30838379
pmcid: 6551451
doi: 10.1093/annonc/mdz048
Lee, J. H., Saw, R. P., Thompson, J. F., Lo, S., Spillane, A. J., Shannon, K. F. et al. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Ann. Oncol. 30, 815–22. (2019).
pubmed: 30860590
pmcid: 6551453
doi: 10.1093/annonc/mdz075
Rothwell, D. G., Ayub, M., Cook, N., Thistlethwaite, F., Carter, L., Dean, E. et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat. Med. 25, 738–43. (2019).
pubmed: 31011204
doi: 10.1038/s41591-019-0380-z
pmcid: 31011204
Gray, E. S., Witkowski, T., Pereira, M., Calapre, L., Herron, K., Irwin, D. et al. Genomic analysis of circulating tumor DNA using a melanoma-specific UltraSEEK oncogene panel. J. Mol. Diagn. 21, 418–26. (2019).
pubmed: 30731208
doi: 10.1016/j.jmoldx.2018.12.001
pmcid: 30731208
Gremel, G., Lee, R. J., Girotti, M. R., Mandal, A. K., Valpione, S., Garner, G. et al. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Ann. Oncol. 27, 1959–1965 (2016).
pubmed: 27502704
pmcid: 5035787
doi: 10.1093/annonc/mdw278
Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat. Med. 25, 1415–21. (2019).
pubmed: 31501609
pmcid: 6741444
doi: 10.1038/s41591-019-0561-9
Forschner, A., Battke, F., Hadaschik, D., Schulze, M., Weissgraeber, S., Han, C. T. et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma—results of a prospective biomarker study. J. Immunother. Cancer 7, 180 (2019).
pubmed: 31300034
pmcid: 6625062
doi: 10.1186/s40425-019-0659-0
Chae, Y. K., Davis, A. A., Agte, S., Pan, A., Simon, N. I., Iams, W. T. et al. Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer. Oncologist 24, 820–828 (2019).
pubmed: 30867242
pmcid: 6656496
doi: 10.1634/theoncologist.2018-0433
Hofman, P., Heeke, S., Alix-Panabieres, C. & Pantel, K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann. Oncol. 30, 1448–59. (2019).
pubmed: 31228184
doi: 10.1093/annonc/mdz196
pmcid: 31228184
Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O., Stern, M. H. et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat. Rev. Clin. Oncol. 15, 639–50. (2018).
pubmed: 30050094
doi: 10.1038/s41571-018-0074-3
pmcid: 30050094
Abbosh, C., Birkbak, N. J. & Swanton, C. Early stage NSCLC—challenges to implementing ctDNA-based screening and MRD detection. Nat. Rev. Clin. Oncol. 15, 577–86. (2018).
pubmed: 29968853
doi: 10.1038/s41571-018-0058-3
pmcid: 29968853
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).
pubmed: 24553385
pmcid: 4017867
doi: 10.1126/scitranslmed.3007094
Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F. et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 20, 430–435 (2014).
pubmed: 24658074
doi: 10.1038/nm.3511
pmcid: 24658074
Parkinson, C. A., Gale, D., Piskorz, A. M., Biggs, H., Hodgkin, C., Addley, H. et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 13, e1002198 (2016).
pubmed: 27997533
pmcid: 5172526
doi: 10.1371/journal.pmed.1002198
Otandault, A., Abraham, J. D., Al Amir Dache, Z., Khalyfa, A., Jariel-Encontre, I., Forne, T. et al. Hypoxia differently modulates the release of mitochondrial and nuclear DNA. Br. J. Cancer. 122, 715–725 (2020).
pubmed: 31929518
pmcid: 7054557
doi: 10.1038/s41416-019-0716-y
Labgaa, I., Villacorta-Martin, C., D’Avola, D., Craig, A. J., von Felden, J., Martins-Filho, S. N. et al. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 37, 3740–3752 (2018).
pubmed: 29628508
pmcid: 6035113
doi: 10.1038/s41388-018-0206-3
Reinert, T., Henriksen, T. V., Christensen, E., Sharma, S., Salari, R., Sethi, H. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol 5, 1124–1131 (2019).
pubmed: 6512280
pmcid: 6512280
doi: 10.1001/jamaoncol.2019.0528
Christensen, E., Birkenkamp-Demtroder, K., Sethi, H., Shchegrova, S., Salari, R., Nordentoft, I. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 1547–1557 (2019).
pubmed: 31059311
doi: 10.1200/JCO.18.02052
pmcid: 31059311
Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat. Med. 25, 1928–1937 (2019).
pubmed: 31768066
pmcid: 7061455
doi: 10.1038/s41591-019-0652-7
Sanchez, C., Snyder, M. W., Tanos, R., Shendure, J. & Thierry, A. R. New insights into structural features and optimal detection of circulating tumor DNA determined by single-strand DNA analysis. npj Genom. Med. 3, 31 (2018).
pubmed: 30479833
pmcid: 6251887
doi: 10.1038/s41525-018-0069-0
Mansukhani, S., Barber, L. J., Kleftogiannis, D., Moorcraft, S. Y., Davidson, M., Woolston, A. et al. Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error-corrected circulating tumor DNA sequencing. Clin. Chem. 64, 1626–1635 (2018).
pubmed: 30150316
pmcid: 6214522
doi: 10.1373/clinchem.2018.289629
Odegaard, J. I., Vincent, J. J., Mortimer, S., Vowles, J. V., Ulrich, B. C., Banks, K. C. et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin. Cancer Res. 24, 3539–3549 (2018).
pubmed: 29691297
doi: 10.1158/1078-0432.CCR-17-3831
pmcid: 29691297
Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J. et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J. Clin. Oncol. 36, 1631–1641 (2018).
pubmed: 29504847
doi: 10.1200/JCO.2017.76.8671
pmcid: 29504847
Strickler, J. H., Loree, J. M., Ahronian, L. G., Parikh, A. R., Niedzwiecki, D., Pereira, A. A. L. et al. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discov. 8, 164–173 (2018).
pubmed: 29196463
doi: 10.1158/2159-8290.CD-17-1009
pmcid: 29196463
Stetson, D., Ahmed, A., Xu, X., Nuttall, B. R. B., Lubinski, T. J., Johnson, J. H. et al. Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance. JCO Precis. Oncol. 3, 1–9 (2019).
Paweletz, C. P., Lau, C. J. & Oxnard, G. R. Does testing error underlie liquid biopsy discordance? JCO Precis. Oncol. 3, 1–3 (2019).
Keller, L. & Pantel, K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat. Rev. Cancer 19, 553–567 (2019).
pubmed: 31455893
doi: 10.1038/s41568-019-0180-2
pmcid: 31455893
Chan, K. C., Jiang, P., Zheng, Y. W., Liao, G. J., Sun, H., Wong, J. et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 59, 211–224 (2013).
pubmed: 23065472
doi: 10.1373/clinchem.2012.196014
pmcid: 23065472
Murtaza, M., Dawson, S. J., Pogrebniak, K., Rueda, O. M., Provenzano, E., Grant, J. et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun. 6, 8760 (2015).
pubmed: 26530965
pmcid: 4659935
doi: 10.1038/ncomms9760
Zhang, Y., Chang, L., Yang, Y., Fang, W., Guan, Y., Wu, A. et al. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Mol. Cancer 18, 7 (2019).
pubmed: 30626401
pmcid: 6325778
doi: 10.1186/s12943-019-0939-9
Zhao, M., Wang, Q., Wang, Q., Jia, P. & Zhao, Z. Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features and perspectives. BMC Bioinforma. 14, S1 (2013).
doi: 10.1186/1471-2105-14-S11-S1
Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D. et al. Global variation in copy number in the human genome. Nature 444, 444–454 (2006).
pubmed: 17122850
pmcid: 2669898
doi: 10.1038/nature05329
Leary, R. J., Sausen, M., Kinde, I., Papadopoulos, N., Carpten, J. D., Craig, D. et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4, 162ra54 (2012).
doi: 10.1126/scitranslmed.3004742
Heitzer, E., Ulz, P., Belic, J., Gutschi, S., Quehenberger, F., Fischereder, K. et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 5, 30 (2013).
pubmed: 23561577
pmcid: 3707016
doi: 10.1186/gm434
Adalsteinsson, V. A., Ha, G., Freeman, S. S., Choudhury, A. D., Stover, D. G., Parsons, H. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1324 (2017).
pubmed: 29109393
pmcid: 5673918
doi: 10.1038/s41467-017-00965-y
Kirkizlar, E., Zimmermann, B., Constantin, T., Swenerton, R., Hoang, B., Wayham, N. et al. Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Transl. Oncol. 8, 407–416 (2015).
pubmed: 26500031
pmcid: 4631096
doi: 10.1016/j.tranon.2015.08.004
Douville, C., Springer, S., Kinde, I., Cohen, J. D., Hruban, R. H., Lennon, A. M. et al. Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs). Proc. Natl Acad. Sci. USA 115, 1871–1876 (2018).
pubmed: 29432176
doi: 10.1073/pnas.1717846115
pmcid: 29432176
Jiang, P., Chan, C. W. M., Chan, K. C. A., Cheng, S. H., Wong, J., Wong, V. W.-S. et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl Acad. Sci. USA 112, E1317–E1325 (2015).
pubmed: 25646427
doi: 10.1073/pnas.1500076112
pmcid: 25646427
Chen, X., Chang, C. W., Spoerke, J. M., Yoh, K. E., Kapoor, V., Baudo, C. et al. Low-pass whole-genome sequencing of circulating cell-free DNA demonstrates dynamic changes in genomic copy number in a squamous lung cancer clinical cohort. Clin. Cancer Res. 25, 2254–2263 (2019).
pubmed: 30617129
doi: 10.1158/1078-0432.CCR-18-1593
pmcid: 30617129
Belic, J., Graf, R., Bauernhofer, T., Cherkas, Y., Ulz, P., Waldispuehl-Geigl, J. et al. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int. J. Cancer 143, 1236–1248 (2018).
pubmed: 29574703
pmcid: 6099279
doi: 10.1002/ijc.31397
Pailler, E., Oulhen, M., Borget, I., Remon, J., Ross, K., Auger, N. et al. Circulating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK-rearranged non-small cell lung cancer patients. Cancer Res. 77, 2222–2230 (2017).
pubmed: 28461563
doi: 10.1158/0008-5472.CAN-16-3072
pmcid: 28461563
Pailler, E., Auger, N., Lindsay, C. R., Vielh, P., Islas-Morris-Hernandez, A., Borget, I. et al. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Ann. Oncol. 26, 1408–1415 (2015).
pubmed: 25846554
pmcid: 4478971
doi: 10.1093/annonc/mdv165
Dagogo-Jack, I., Rooney, M., Nagy, R. J., Lin, J. J., Chin, E., Ferris, L. A. et al. Molecular analysis of plasma from patients with ROS1-positive NSCLC. J. Thorac. Oncol. 14, 816–824 (2019).
pubmed: 30664990
pmcid: 6486857
doi: 10.1016/j.jtho.2019.01.009
Dagogo-Jack, I., Brannon, A. R., Ferris, L. A., Campbell, C. D., Lin, J. J., Schultz, K. R. et al. Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA. JCO Precis. Oncol. (2018). https://doi.org/10.1200/PO.17.00160 .
Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D. et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659–1665 (2001).
pubmed: 11245480
pmcid: 11245480
Giacona, M. B., Ruben, G. C., Iczkowski, K. A., Roos, T. B., Porter, D. M. & Sorenson, G. D. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17, 89–97 (1998).
pubmed: 9667526
doi: 10.1097/00006676-199807000-00012
pmcid: 9667526
Nagata, S. Apoptotic DNA fragmentation. Exp. Cell Res. 256, 12–18 (2000).
pubmed: 10739646
doi: 10.1006/excr.2000.4834
pmcid: 10739646
Wang, B. G., Huang, H. Y., Chen, Y. C., Bristow, R. E., Kassauei, K., Cheng, C. C. et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 63, 3966–3968 (2003).
pubmed: 12873992
pmcid: 12873992
Underhill, H. R., Kitzman, J. O., Hellwig, S., Welker, N. C., Daza, R., Baker, D. N. et al. Fragment length of circulating tumor DNA. PLoS Genet. 12, e1006162 (2016).
pubmed: 27428049
pmcid: 4948782
doi: 10.1371/journal.pgen.1006162
Mouliere, F., Chandrananda, D., Piskorz, A. M., Moore, E. K., Morris, J., Ahlborn, L. B. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. 10, eaat4921 (2018).
pubmed: 30404863
pmcid: 6483061
doi: 10.1126/scitranslmed.aat4921
Mouliere, F., Robert, B., Arnau Peyrotte, E., Del Rio, M., Ychou, M., Molina, F. et al. High fragmentation characterizes tumour-derived circulating DNA. PloS ONE 6, e23418 (2011).
pubmed: 21909401
pmcid: 3167805
doi: 10.1371/journal.pone.0023418
Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adleff, V., Bruhm, D. C. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385–389 (2019).
pubmed: 31142840
pmcid: 6774252
doi: 10.1038/s41586-019-1272-6
Bronkhorst, A. J., Wentzel, J. F., Aucamp, J., van Dyk, E., du Plessis, L. & Pretorius, P. J. Characterization of the cell-free DNA released by cultured cancer cells. Biochim. Biophys. Acta 1863, 157–165 (2016).
pubmed: 26529550
doi: 10.1016/j.bbamcr.2015.10.022
pmcid: 26529550
Norris, A. L., Workman, R. E., Fan, Y., Eshleman, J. R. & Timp, W. Nanopore sequencing detects structural variants in cancer. Cancer Biol. Ther. 17, 246–253 (2016).
pubmed: 26787508
pmcid: 4848001
doi: 10.1080/15384047.2016.1139236
Mouliere, F., Mair, R., Chandrananda, D., Marass, F., Smith, C. G., Su, J. et al. Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Mol. Med. 10, e9323 (2018).
pubmed: 30401727
pmcid: 6284385
doi: 10.15252/emmm.201809323
Markus, H., Zhao, J., Contente-Cuomo, T., Raupach, E., Odenheimer-Bergman, A., Connor, S. et al. Sub-nucleosomal organization in urine cell-free DNA. bioRxiv. (2019). https://www.biorxiv.org/content/biorxiv/early/2019/07/11/696633.full.pdf .
Burnham, P., Dadhania, D., Heyang, M., Chen, F., Westblade, L. F., Suthanthiran, M. et al. Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. Nat. Commun. 9, 2412 (2018).
pubmed: 29925834
pmcid: 6010457
doi: 10.1038/s41467-018-04745-0
Cook, L., Starr, K., Boonyaratanakornkit, J., Hayden, R., Sam, S. S. & Caliendo, A. M. Does size matter? Comparison of wxtraction yields for different-sized DNA fragments by seven different routine and four new circulating cell-free extraction methods. J. Clin. Microbiol. 56, e01061–18 (2018).
pubmed: 30282788
pmcid: 6258844
doi: 10.1128/JCM.01061-18
Markus, H., Contente-Cuomo, T., Farooq, M., Liang, W. S., Borad, M. J., Sivakumar, S. et al. Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci. Rep. 8, 7375 (2018).
pubmed: 29743667
pmcid: 5943304
doi: 10.1038/s41598-018-25810-0
Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57–68 (2016).
pubmed: 26771485
pmcid: 4715266
doi: 10.1016/j.cell.2015.11.050
Cheng, T. H. T., Lui, K. O., Peng, X. L., Cheng, S. H., Jiang, P., Chan, K. C. A. et al. DNase1 does not appear to play a major role in the fragmentation of plasma DNA in a knockout mouse model. Clin. Chem. 64, 406–408 (2018).
pubmed: 29097509
doi: 10.1373/clinchem.2017.280446
pmcid: 29097509
Henikoff, S. Nucleosome destabilization in the epigenetic regulation of gene expression. Nat. Rev. Genet. 9, 15–26 (2008).
pubmed: 18059368
doi: 10.1038/nrg2206
pmcid: 18059368
Ivanov, M., Baranova, A., Butler, T., Spellman, P. & Mileyko, V. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics. 16, S1 (2015).
pubmed: 26693644
pmcid: 4686799
doi: 10.1186/1471-2164-16-S13-S1
Ulz, P., Thallinger, G. G., Auer, M., Graf, R., Kashofer, K., Jahn, S. W. et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat. Genet. 48, 1273–1278 (2016).
pubmed: 27571261
doi: 10.1038/ng.3648
pmcid: 27571261
Sun, K., Jiang, P., Cheng, S. H., Cheng, T. H. T., Wong, J., Wong, V. W. S. et al. Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Res. 29, 418–427 (2019).
pubmed: 30808726
pmcid: 6396422
doi: 10.1101/gr.242719.118
Valouev, A., Johnson, S. M., Boyd, S. D., Smith, C. L., Fire, A. Z. & Sidow, A. Determinants of nucleosome organization in primary human cells. Nature 474, 516–520 (2011).
pubmed: 21602827
pmcid: 3212987
doi: 10.1038/nature10002
Teif, V. B., Vainshtein, Y., Caudron-Herger, M., Mallm, J. P., Marth, C., Hofer, T. et al. Genome-wide nucleosome positioning during embryonic stem cell development. Nat. Struct. Mol. Biol. 19, 1185–1192 (2012).
pubmed: 23085715
doi: 10.1038/nsmb.2419
pmcid: 23085715
Ulz, P., Perakis, S., Zhou, Q., Moser, T., Belic, J., Lazzeri, I. et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat. Commun. 10, 4666 (2019).
pubmed: 31604930
pmcid: 6789008
doi: 10.1038/s41467-019-12714-4
Jaenisch, R. & Bird, A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33, 245–254 (2003).
pubmed: 12610534
doi: 10.1038/ng1089
pmcid: 12610534
Yong, W. S., Hsu, F. M. & Chen, P. Y. Profiling genome-wide DNA methylation. Epigenetics Chromatin. 9, 26 (2016).
pubmed: 27358654
pmcid: 4926291
doi: 10.1186/s13072-016-0075-3
Kurdyukov, S. & Bullock, M. DNA methylation analysis: choosing the right method. Biology (Basel). 5, (2016). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810160/pdf/biology-05-00003.pdf .
Liu, Z., Wang, Z., Jia, E., Ouyang, T., Pan, M., Lu, J. et al. Analysis of genome-wide in cell free DNA methylation: progress and prospect. Analyst. 144, 5912–5922 (2019).
pubmed: 31436778
doi: 10.1039/C9AN00935C
pmcid: 31436778
Shen, S. Y., Singhania, R., Fehringer, G., Chakravarthy, A., Roehrl, M. H. A., Chadwick, D. et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 563, 579–583 (2018).
pubmed: 30429608
doi: 10.1038/s41586-018-0703-0
pmcid: 30429608
De Koker, A., Van Paemel, R., De Wilde, B., De Preter, K.& Callewaert, N. A versatile method for circulating cell-free DNA methylome profiling by reduced representation bisulfite sequencing. bioRxiv. (2019). https://www.biorxiv.org/content/biorxiv/early/2019/06/11/663195.full.pdf .
Gai, W. & Sun, K. Epigenetic biomarkers in cell-free DNA and applications in liquid biopsy. Genes (Basel) 10, (2019). https://doi.org/10.3390/genes10010032 .
Warton, K., Mahon, K. L. & Samimi, G. Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr. Relat. Cancer 23, R157–R171 (2016).
pubmed: 26764421
pmcid: 4737995
doi: 10.1530/ERC-15-0369
Li, L., Fu, K., Zhou, W. & Snyder, M. Applying circulating tumor DNA methylation in the diagnosis of lung cancer. Precis. Clin. Med. 2, 45–56 (2019).
doi: 10.1093/pcmedi/pbz003
Wu, A., Cremaschi, P., Wetterskog, D., Conteduca, V., Franceschini, G. M., Kleftogiannis, D. et al. Genome-wide plasma DNA methylation features of metastatic prostate cancer. J. Clin. Invest. 130, 1991–2000 (2020).
pubmed: 32149736
pmcid: 7108919
doi: 10.1172/JCI130887
Jones, P. A., Ohtani, H., Chakravarthy, A. & De Carvalho, D. D. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer 19, 151–61. (2019).
pubmed: 30723290
doi: 10.1038/s41568-019-0109-9
pmcid: 30723290
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R. et al. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 40, 328–344 (2019).
pubmed: 30853334
doi: 10.1016/j.it.2019.02.004
pmcid: 30853334
Xu, R. H., Wei, W., Krawczyk, M., Wang, W., Luo, H., Flagg, K. et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat. Mater. 16, 1155–1161 (2017).
pubmed: 29035356
doi: 10.1038/nmat4997
pmcid: 29035356
Roadmap Epigenomics, C., Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).
doi: 10.1038/nature14248
Poon, L. L., Leung, T. N., Lau, T. K., Chow, K. C. & Lo, Y. M. Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma. Clin. Chem. 48, 35–41 (2002).
pubmed: 11751536
doi: 10.1093/clinchem/48.1.35
pmcid: 11751536
Lun, F. M., Chiu, R. W., Sun, K., Leung, T. Y., Jiang, P., Chan, K. C. et al. Noninvasive prenatal methylomic analysis by genomewide bisulfite sequencing of maternal plasma DNA. Clin. Chem. 59, 1583–1594 (2013).
pubmed: 23857673
doi: 10.1373/clinchem.2013.212274
pmcid: 23857673
Lehmann-Werman, R., Neiman, D., Zemmour, H., Moss, J., Magenheim, J., Vaknin-Dembinsky, A. et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc. Natl Acad. Sci. USA 113, E1826–E1834 (2016).
pubmed: 26976580
doi: 10.1073/pnas.1519286113
pmcid: 26976580
Sun, K., Jiang, P., Chan, K. C., Wong, J., Cheng, Y. K., Liang, R. H. et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl Acad. Sci. USA 112, E5503–E5512 (2015).
pubmed: 26392541
doi: 10.1073/pnas.1508736112
pmcid: 26392541
Gai, W., Ji, L., Lam, W. K. J., Sun, K., Jiang, P., Chan, A. W. H. et al. Liver- and colon-specific DNA methylation markers in plasma for investigation of colorectal cancers with or without liver metastases. Clin. Chem. 64, 1239–1249 (2018).
pubmed: 29903871
doi: 10.1373/clinchem.2018.290304
pmcid: 29903871
Liao, J. B. Viruses and human cancer. Yale J. Biol. Med. 79, 115–122 (2006).
pubmed: 17940621
pmcid: 17940621
Farrell, P. J. Epstein-Barr virus and cancer. Annu. Rev. Pathol. 14, 29–53 (2019).
pubmed: 30125149
doi: 10.1146/annurev-pathmechdis-012418-013023
pmcid: 30125149
Borsetto, D., Cheng, J., Payne, K., Nankivell, P., Batis, N., Rao, K. et al. Surveillance of HPV-positive head and neck squamous cell carcinoma with circulating and salivary DNA biomarkers. Crit. Rev. Oncog. 23, 235–245 (2018).
pubmed: 30311577
doi: 10.1615/CritRevOncog.2018027689
pmcid: 30311577
Cheung, T. H., Yim, S. F., Yu, M. Y., Worley, M. J. Jr, Fiascone, S. J., Chiu, R. W. K. et al. Liquid biopsy of HPV DNA in cervical cancer. J. Clin. Virol. 114, 32–36 (2019).
pubmed: 30913520
doi: 10.1016/j.jcv.2019.03.005
pmcid: 30913520
Cocuzza, C. E., Martinelli, M., Sina, F., Piana, A., Sotgiu, G., Dell’Anna, T. et al. Human papillomavirus DNA detection in plasma and cervical samples of women with a recent history of low grade or precancerous cervical dysplasia. PloS ONE 12, e0188592 (2017).
pubmed: 29182627
pmcid: 5705130
doi: 10.1371/journal.pone.0188592
Jensen, K. K., Gronhoj, C., Jensen, D. H. & von Buchwald, C. Circulating human papillomavirus DNA as a surveillance tool in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Clin. Otolaryngol. 43, 1242–1249 (2018).
pubmed: 29763978
doi: 10.1111/coa.13136
pmcid: 29763978
Ahn, S. M., Chan, J. Y., Zhang, Z., Wang, H., Khan, Z., Bishop, J. A. et al. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol. Head Neck Surg. 140, 846–854 (2014).
pubmed: 25078109
pmcid: 4313904
doi: 10.1001/jamaoto.2014.1338
Wang, Y., Springer, S., Mulvey, C. L., Silliman, N., Schaefer, J., Sausen, M. et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci. Transl. Med. 7, 293ra104 (2015).
pubmed: 26109104
pmcid: 4587492
doi: 10.1126/scitranslmed.aaa8507
Hanna, G. J., Lau, C. J., Mahmood, U., Supplee, J. G., Mogili, A. R., Haddad, R. I. et al. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral. Oncol. 95, 120–126 (2019).
pubmed: 31345379
doi: 10.1016/j.oraloncology.2019.06.019
pmcid: 31345379
Schmidt, H., Kulasinghe, A., Allcock, R. J. N., Tan, L. Y., Mokany, E., Kenny, L. et al. A pilot study to non-invasively track PIK3CA mutation in head and neck cancer. Diagnostics (Basel). 8, (2018). https://doi.org/10.3390/diagnostics8040079 .
Lam, W. K. J., Chan, K. C. A. & Lo, Y. M. D. Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. J. Pathol. 247, 641–649 (2019).
pubmed: 30714167
pmcid: 6594142
doi: 10.1002/path.5249
Lo, Y. M., Chan, A. T., Chan, L. Y., Leung, S. F., Lam, C. W., Huang, D. P. et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 60, 6878–6881 (2000).
pubmed: 11156384
pmcid: 11156384
Chen, Q. Y., Guo, S. Y., Tang, L. Q., Lu, T. Y., Chen, B. L., Zhong, Q. Y. et al. Combination of tumor volume and Epstein-Barr vrus DNA improved prognostic stratification of stage II nasopharyngeal carcinoma in the intensity modulated radiotherapy era: a large-scale cohort study. Cancer Res. Treat. 50, 861–871 (2018).
pubmed: 28903550
doi: 10.4143/crt.2017.237
pmcid: 28903550
Leung, S. F., Chan, K. C., Ma, B. B., Hui, E. P., Mo, F., Chow, K. C. et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann. Oncol. 25, 1204–1208 (2014).
pubmed: 24638904
doi: 10.1093/annonc/mdu117
pmcid: 24638904
Chen, Q., Hu, W., Xiong, H., Ying, S., Ruan, Y., Wu, B. et al. Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy. Diagn. Pathol. 14, 23 (2019).
pubmed: 30871579
pmcid: 6417170
doi: 10.1186/s13000-019-0798-0
Chan, K. C. A., Woo, J. K. S., King, A., Zee, B. C. Y., Lam, W. K. J., Chan, S. L. et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513–522 (2017).
pubmed: 28792880
doi: 10.1056/NEJMoa1701717
pmcid: 28792880
He, S. S., Wang, Y., Bao, Y., Cai, X. Y., Yang, X. L., Chen, D. M. et al. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study. Cancer Med. 7, 1110–1117 (2018).
pubmed: 29493874
pmcid: 5911595
doi: 10.1002/cam4.1381
Lv, J., Chen, Y., Zhou, G., Qi, Z., Tan, K. R. L., Wang, H. et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat. Commun. 10, 3941 (2019).
pubmed: 31477699
pmcid: 6718666
doi: 10.1038/s41467-019-11853-y
Lam, W. K. J., Jiang, P., Chan, K. C. A., Cheng, S. H., Zhang, H., Peng, W. et al. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc. Natl Acad. Sci. USA 115, E5115–E5124 (2018).
pubmed: 29760067
doi: 10.1073/pnas.1804184115
pmcid: 29760067
Qiu, M. Z., He, C. Y., Lu, S. X., Guan, W. L., Wang, F., Wang, X. J. et al. Prospective observation: clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients. Int. J. Cancer. 146, 272–280 (2019).
pubmed: 31162842
doi: 10.1002/ijc.32490
pmcid: 31162842
To, E. W., Chan, K. C., Leung, S. F., Chan, L. Y., To, K. F., Chan, A. T. et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin. Cancer Res. 9, 3254–3259 (2003).
pubmed: 12960110
pmcid: 12960110
Lampignano, R., Neumann, M. H. D., Weber, S., Kloten, V., Herdean, A., Voss, T. et al. Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (Pre)analytical work flows. Clin. Chem. 66, 149–160 (2019).
doi: 10.1373/clinchem.2019.306837
Meddeb, R., Dache, Z. A. A., Thezenas, S., Otandault, A., Tanos, R., Pastor, B. et al. Quantifying circulating cell-free DNA in humans. Sci. Rep. 9, 5220 (2019).
pubmed: 30914716
pmcid: 6435718
doi: 10.1038/s41598-019-41593-4
Anfossi, S., Babayan, A., Pantel, K. & Calin, G. A. Clinical utility of circulating non-coding RNAs—an update. Nat. Rev. Clin. Oncol. 15, 541–563 (2018).
pubmed: 29784926
doi: 10.1038/s41571-018-0035-x
pmcid: 29784926
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926–930 (2018).
pubmed: 29348365
pmcid: 6080308
doi: 10.1126/science.aar3247
Pantel, K. & Alix-Panabieres, C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol. Med. 16, 398–406 (2010).
pubmed: 20667783
doi: 10.1016/j.molmed.2010.07.001
pmcid: 20667783
Murtaza, M. & Caldas, C. Nucleosome mapping in plasma DNA predicts cancer gene expression. Nat. Genet. 48, 1105–1106 (2016).
pubmed: 27681289
doi: 10.1038/ng.3686
pmcid: 27681289
Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F. et al. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA. Sci. Trans. Med 4, 136ra68 (2012).
doi: 10.1126/scitranslmed.3003726
De Mattos-Arruda, L., Weigelt, B., Cortes, J., Won, H. H., Ng, C. K. Y., Nuciforo, P. et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 25, 1729–1735 (2014).
pubmed: 25009010
pmcid: 6276937
doi: 10.1093/annonc/mdu239
Khan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T. et al. Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discov. 8, 1270–1285 (2018).
pubmed: 30166348
pmcid: 6380469
doi: 10.1158/2159-8290.CD-17-0891
Jamal-Hanjani, M., Wilson, G. A., Horswell, S., Mitter, R., Sakarya, O., Constantin, T. et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann. Oncol. 27, 862–867 (2016).
pubmed: 26823523
doi: 10.1093/annonc/mdw037
pmcid: 26823523
Gao, J., Wang, H., Zang, W., Li, B., Rao, G., Li, L. et al. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Sci. 108, 1881–1887 (2017).
pubmed: 28677165
pmcid: 5581520
doi: 10.1111/cas.13314
Bernard-Tessier, A., Jeannot, E., Guenat, D., Debernardi, A., Michel, M., Proudhon, C. et al. Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. Clin. Cancer Res. 25, 2109–2115 (2019).
pubmed: 30504426
doi: 10.1158/1078-0432.CCR-18-2984
pmcid: 30504426
Cabel, L., Jeannot, E., Bieche, I., Vacher, S., Callens, C., Bazire, L. et al. Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. Clin. Cancer Res. 24, 5767–5771 (2018).
pubmed: 30054279
doi: 10.1158/1078-0432.CCR-18-0922
pmcid: 30054279
Carow, K., Golitz, M., Wolf, M., Hafner, N., Jansen, L., Hoyer, H. et al. Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA. Int. J. Mol. Sci. 18, 2032 (2017).
pmcid: 5666714
doi: 10.3390/ijms18102032
Kang, Z., Stevanovic, S., Hinrichs, C. S. & Cao, L. Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring. Clin. Cancer Res. 23, 6856–6862 (2017).
pubmed: 28899967
doi: 10.1158/1078-0432.CCR-17-1553
pmcid: 28899967
Jeannot, E., Becette, V., Campitelli, M., Calmejane, M. A., Lappartient, E., Ruff, E. et al. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma. J Pathol. Clin. Res. 2, 201–209 (2016).
pubmed: 27917295
pmcid: 5129558
doi: 10.1002/cjp2.47
Sathish, N., Abraham, P., Peedicayil, A., Sridharan, G., John, S., Shaji, R. V. et al. HPV DNA in plasma of patients with cervical carcinoma. J. Clin. Virol. 31, 204–209 (2004).
pubmed: 15465413
doi: 10.1016/j.jcv.2004.03.013
pmcid: 15465413
Campitelli, M., Jeannot, E., Peter, M., Lappartient, E., Saada, S., de la Rochefordiere, A. et al. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PloS ONE. 7, e43393 (2012).
pubmed: 22937045
pmcid: 3427328
doi: 10.1371/journal.pone.0043393
Mazurek, A. M., Rutkowski, T., Fiszer-Kierzkowska, A., Malusecka, E. & Skladowski, K. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral oncology 54, 36–41 (2016).
pubmed: 26786940
doi: 10.1016/j.oraloncology.2015.12.002
pmcid: 26786940
Capone, R. B., Pai, S. I., Koch, W. M., Gillison, M. L., Danish, H. N., Westra, W. H. et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 6, 4171–4175 (2000).
Dahlstrom, K. R., Li, G., Hussey, C. S., Vo, J. T., Wei, Q., Zhao, C. et al. Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. Cancer 121, 3455–3464 (2015).
pubmed: 26094818
pmcid: 4575612
doi: 10.1002/cncr.29538
Cao, H., Banh, A., Kwok, S., Shi, X., Wu, S., Krakow, T. et al. Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. International journal of radiation oncology, biology, physics 82, e351–e358 (2012).
pubmed: 21985946
doi: 10.1016/j.ijrobp.2011.05.061
pmcid: 21985946